RA Capital Management 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 85 US equity positions worth $9.5bn in its Q1 2026 13F filing. The largest position was ASND at 24.8% of the reported book, followed by PCVX and RYTM. Against the Q4 2025 filing, it opened 9 new positions, added to 11 and reduced 1 among the top 50 holdings.
What did RA Capital Management own in Q1 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S - ADR | Healthcare | 24.8% | $2.4bn | 10,281,496 | 0% | held |
| 2 | PCVX VAXCYTE INC | Healthcare | 7.0% | $666.8m | 11,474,599 | 7% | added |
| 3 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 6.1% | $579.8m | 6,666,837 | 0% | held |
| 4 | TYRA TYRA BIOSCIENCES INC | Healthcare | 4.9% | $467.2m | 12,198,625 | 0% | held |
| 5 | SION SIONNA THERAPEUTICS INC | 4.2% | $397.1m | 9,905,045 | 0% | held | |
| 6 | EWTX EDGEWISE THERAPEUTICS INC | 3.5% | $328.5m | 10,428,437 | 0% | held | |
| 7 | NEWAMSTERDAM PHARMA CO NV | 3.2% | $305.7m | 9,550,191 | 0% | held | |
| 8 | NUVALENT INC-A | 2.7% | $259.6m | 2,534,145 | 35% | added | |
| 9 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 2.3% | $219.2m | 2,611,733 | 62% | added |
| 10 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 2.2% | $208.4m | 7,692,750 | 5% | added |
| 11 | SPYGLASS PHARMA INC | 2.2% | $207.8m | 8,021,117 | – | new | |
| 12 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 2.1% | $195.6m | 26,975,505 | 48% | added |
| 13 | SEPN SEPTERNA INC | 1.8% | $168.1m | 6,995,858 | 0% | held | |
| 14 | IRON DISC MEDICINE INC | Healthcare | 1.7% | $156.7m | 2,450,221 | 24% | added |
| 15 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.6% | $155.5m | 11,189,693 | 0% | held |
| 16 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 1.6% | $150.7m | 15,827,186 | 0% | held |
| 17 | BCAX BICARA THERAPEUTICS INC | 1.5% | $144.3m | 7,255,993 | 4% | added | |
| 18 | CLYM CLIMB BIO INC | 1.3% | $120.8m | 11,300,939 | 0% | held | |
| 19 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.3% | $120.4m | 373,787 | 0% | held |
| 20 | GHRS GH RESEARCH PLC | 1.1% | $107.9m | 7,676,697 | 0% | held | |
| 21 | ZLAB ZAI LAB LTD-ADR | Healthcare | 1.1% | $107.4m | 5,707,262 | – | new |
| 22 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.1% | $105.3m | 23,555,648 | 0% | held |
| 23 | VOR VOR BIOPHARMA INC | 1.0% | $96.4m | 5,404,998 | 0% | held | |
| 24 | GERN GERON CORP | Healthcare | 1.0% | $95.0m | 63,771,366 | 0% | held |
| 25 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.9% | $87.2m | 10,860,977 | 0% | held |
| 26 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 0.9% | $84.9m | 3,902,596 | – | new |
| 27 | SYRE SPYRE THERAPEUTICS INC | 0.9% | $81.8m | 1,621,620 | 0% | held | |
| 28 | EVMN EVOMMUNE INC | 0.8% | $80.3m | 3,494,638 | 1% | added | |
| 29 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.7% | $67.2m | 9,339,978 | 61% | added |
| 30 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.7% | $63.5m | 9,853,302 | 0% | held | |
| 31 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 0.7% | $62.1m | 2,399,310 | – | new |
| 32 | XNCR XENCOR INC | Healthcare | 0.6% | $59.1m | 4,897,237 | – | new |
| 33 | LB PHARMACEUTICALS INC | 0.6% | $54.5m | 2,208,604 | 0% | held | |
| 34 | JBIO JADE BIOSCIENCES INC | 0.5% | $51.6m | 3,671,083 | 0% | held | |
| 35 | ABOS ACUMEN PHARMACEUTICALS INC | 0.5% | $49.5m | 20,992,669 | 41% | added | |
| 36 | 4D MOLECULAR THERAPEUTICS IN | 0.5% | $47.0m | 5,049,779 | -11% | reduced | |
| 37 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.5% | $46.4m | 6,053,960 | 0% | held |
| 38 | CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 0.5% | $45.8m | 1,507,844 | 0% | held |
| 39 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.4% | $40.1m | 17,754,430 | – | new |
| 40 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 0.4% | $38.8m | 2,600,000 | 0% | held |
| 41 | LENZ LENZ THERAPEUTICS INC | Healthcare | 0.4% | $38.2m | 4,178,823 | 0% | held |
| 42 | MNPR MONOPAR THERAPEUTICS INC | 0.4% | $36.6m | 667,207 | 0% | held | |
| 43 | PEPG PEPGEN INC | Healthcare | 0.4% | $35.5m | 20,064,545 | 0% | held |
| 44 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.3% | $31.6m | 2,972,973 | 103% | added |
| 45 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 0.3% | $29.4m | 318,554 | – | new |
| 46 | BIOA BIOAGE LABS INC | 0.3% | $28.9m | 1,650,648 | – | new | |
| 47 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.3% | $28.7m | 5,000,000 | 0% | held |
| 48 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 0.3% | $28.3m | 1,020,410 | 0% | held |
| 49 | RZLT REZOLUTE INC | 0.3% | $28.0m | 9,180,000 | 0% | held | |
| 50 | AKTS AKTIS ONCOLOGY INC | 0.3% | $26.9m | 1,503,084 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.